Shenzhen Neptunus Interlong Bio-technique Company Limited (Stock Code: 8329) announced the renewal of its sales framework agreement with Shenzhen Neptunus Group Company Limited (Neptunus Group) for the three-year period from 1 January 2026 to 31 December 2028, following the impending expiry of the existing arrangement on 31 December 2025.

According to the announcement, the group will continue supplying certain self-manufactured or distributed products, such as pharmaceutical products, healthcare food items, and medical devices, to Neptunus Group. The proposed annual caps under the new agreement (excluding VAT) are set at RMB56 million (approximately HK$60.59 million) for 2026, RMB62 million (approximately HK$67.08 million) for 2027, and RMB69 million (approximately HK$74.66 million) for 2028.

The transaction constitutes a continuing connected transaction under the GEM Listing Rules, as Neptunus Group is an associate of Shenzhen Neptunus Bio-engineering, the controlling shareholder of Shenzhen Neptunus Interlong. One or more applicable percentage ratios exceed 5%, triggering reporting, announcement, annual review, and independent shareholders’ approval requirements.

An extraordinary general meeting (EGM) will be convened to seek independent shareholders’ approval of the renewed framework agreement and its proposed sales caps. The company formed an Independent Board Committee composed of three independent non-executive directors and appointed Gram Capital Limited as the independent financial adviser. A circular containing further details on the agreement, along with letters from the Independent Board Committee and the independent financial adviser, will be dispatched as soon as practicable.